Biotech News
aTyr Pharma Presents Preclinical Data for NRP2-Targeting Antibody ATYR2810 at the Connective Tissue Oncology Society (CTOS) 2026 Annual Meeting
ATYR2810 substantially inhibits tumor growth and metastasis of osteosarcoma to the lungs, the main driver of poor outcomes, in preclinical studies. Anti-tumor benefits continued after treatment with ATYR2810 ended, without evidence of overt toxicity, supporting the potential of ATYR2810 in an
